Saturday November 1, 2014
SNc Channels:

Search
About Salem-News.com
Zip Weather


Weather Forecast
Keizer is a thriving community near Salem, Oregon

 

Sep-27-2011 00:33printcomments

Is Purdue Pharma Using Kids as Guinea Pigs?

"It is not truth that matters, but victory." Adolf Hitler

Kids as big pharma guinea pigs

(MYRTLE BEACH, S.C.) - On April 23, 2011 I wrote an article for Salem-News.com on children being used as guinea pigs by Purdue Pharma in clinical trials of OxyContin -- ages 6 to 16. See link below.

I questioned why the FDA and government agencies were allowing these clinical trials to take place in view of the epidemic this country has experienced with death, addiction and abuse because of the lies used in the marketing of OxyContin.

In the recruitment filing Purdue Pharma was using to market for young children, it said "This study is currently recruiting participants - verified on March 2011 by Purdue Pharma." Shortly after my article was published, there was a change of recruitment in June 2011 where Purdue Pharma indicates they are not recruiting participants. This doesn't mean that they won't be recruiting children at a later date -- but it does keep the children in the U.S. and Canada safe (for now) from becoming addicted to a very dangerous drug that Purdue Pharma is aware should not be given to children.

I received the below information by mail from someone in the medical profession who questions Purdue Pharma being allowed to market OxyContin to children in the treatment of pain. Maybe the FDA would like to respond to the following questions and statements before our childrens' lives are taken by Purdue Pharma in death and addiction: For Dr. Steiner to be listed as an investigator condoning the administration of up to 240 mg/day of OxyCondone to a child is absolutely criminal.

Study of Oxycodone HCI CR 20 to 240 mg/day for the management of moderate to severe malignant or nonmalignant pain - Investigator: Deborah Steiner, MD (Purdue Pharma):

1. In the study: Purdue Pharma LP Clinical Trials. gov Identifier: NCT01369615, the operational definition of "moderate to severe pain" is based on an expert investigator's judgement. What would be the reliability of accurate diagnostic agreement if untrained, non specialized pain management doctors who are practicing in the field are eventually given the power to determine what non malignant "moderate to severe pain" is?

2. If the use of this drug is approved based on this study, couldn't a parent's pressure that they don't want their child to be in any pain unduly influence the prescription of such opiates by doctors to kids?

3. Once a child is prescribed, the doses currently being evaluated in this study, there is no way addressed as to assess when to eventually decrease or stop these medications. Unlike antibiotics where a full course of treatment is needed in pain management how will we know when it is time to cut down or stop?

4. Based upon known literature already established by the FDA, if a child were to actually take this study's recommendations of an around the clock "20-mg daily dose of Oxycodone for at least 2 weeks" the chances of biological dependence could be serious.

5. There is nothing in the study which addressed how the child's possible dependence would then be treated. Would an undereducated, non specialist clinician in the field just let the child go "cold turkey." Remember an opiate has both the potential for biological and psychological addiction. Where in this study are these complex issues addressed?

6. There is current data being investigated by a multi discipline high level task force in New York State which has identified a real present danger of a potential "gateway" from prescription opiates to street heroin. An Oxycodone pill on the street may cost $10 - 15 per pill. Law enforcement has shown that it is cheaper and easier for many to turn from opiates to heroin. So what starts as a medically prescribed opiate for pain may turn into a street addiction of heroin.

7. The ages proposed in this study are the adolescent years, i.e. 13 - 16. A prime time or vulnerability of substance abuse. The study doesn't address what it would be like for an adolescent who is potentially already self medicating with alcohol for example to also now be introduced to an opiate. Are we creating the potential for cross and complex mixed addictions?

8. There is no routine testing in the study that the population is not also doing other substances, i.e. alcohol at the same time of the administration of Oxycodone so how do we know what is really treating the pain?

9. In the real world of adolescent medicine, what are the chances that a 16 year old who has now been given a legal prescription for Oxycodone won't also try to mix it with alcohol or other substances to get high?

10. These pills won't be cheap. In rising health care costs introducing another patented pain killer may make the taxpayer and health insurer think long and hard about the cost benefit ratio compared to already available generics.

So what do you think FDA and law officials in every state in the country -- are you going to allow Purdue Pharma to continue their reign of death and addiction -- but now directed at our children? Or will you protect our children from the continued Holocaust you have allowed Purdue Pharma to perpetuate in this country?

http://www.salem-news.com/articles/april232011/oxycontin-deaths-ms.php

LP - "Your talent is God's gift to you. What you do with it is your gift back to God." Leo Buscaglia.  .



Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

This study is currently recruiting participants.

Verified on March 2011 by Purdue Pharma LP

First Received on August 30, 2010. Last Updated on March 28, 2011 History of Changes

Sponsor: Purdue Pharma LP
Information provided by: Purdue Pharma LP
ClinicalTrials.gov Identifier: NCT01192295

Purpose

The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years, inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy.


Condition Intervention Phase
Pain
Drug: Oxycodone HCl controlled-release tablets
Phase III

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label

Primary Purpose: Treatment

Official Title: An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgesics

Resource links provided by NLM:


Further study details as provided by Purdue Pharma LP:

Primary Outcome Measures:
  • The number of participants with adverse events as a measure of safety. [ Time Frame: Up to 4 weeks (during the study) and 7-10 days poststudy (safety follow-up assessment). ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

  • To characterize the efficacy and provide additional pharmacokinetics (PK) data of oxycodone hydrochloride controlled-release tablets [ Time Frame: 2-4 and 4-6 hours (hrs) after the first dose on Day 1 and immediately pre-dose and 2-4 hrs after dose at Visit 2 and/or Visit 3. ] [ Designated as safety issue: No ]

    To characterize the efficacy and provide additional pharmacokinetics (PK) data for a population PK model of oxycodone hydrochloride controlled-release tablets in opioid tolerant pediatric patients aged 6 to16 years, inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy.


Estimated Enrollment: 135
Study Start Date: November 2010
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Oxycodone HCl controlled-release: Experimental

Oxycodone hydrochloride (HCl) controlled-release (CR)

Intervention: Drug: Oxycodone HCl controlled-release tablets
Drug: Oxycodone HCl controlled-release tablets

Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.


Eligibility

Ages Eligible for Study: 6 Years to 16 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria include:

  • Male and female patients aged 6 to 16 years, inclusive, who are expected to require ongoing around-the-clock opioid treatment equivalent to at least 20-mg daily dose of oxycodone for at least 2 weeks for management of moderate to severe (based on the investigator's judgment) malignant or nonmalignant pain.
  • Patients must be opioid tolerant, ie, have been treated with opioids for at least the 5 consecutive days prior to dosing and with at least 20 mg daily of oxycodone or the equivalent during at least the last 48 hours prior to the start of study drug dosing and have tolerated the therapy, as demonstrated at the start of study drug dosing.
  • Patients who are currently using transdermal fentanyl should have been on the patch for at least 3 days before removing the patch and oxycodone hydrochloride (HCl) controlled-release (CR) treatment can only be initiated at least 18 hours following the removal of the transdermal fentanyl patch.
  • Patients must not require more than a 240-mg total daily dose of oxycodone HCl CR tablets.
  • Patients must be willing and able to swallow the oxycodone HCl CR tablets whole.
  • Patients must not be currently on an investigational medication/therapy at the start of screening or during the study.

Exclusion Criteria include:

  • Female patients who are pregnant or lactating.
  • Patients who are allergic to oxycodone or have a history of allergies to other opioids (this criterion does not include patients who have experienced common opioid side effects [eg, nausea, constipation]).
  • Patients who have received epidural opioids < 2 hours prior to the first dose of study drug or who have received epidural morphine < 12 hours prior to the first dose of study drug.
  • Patients who are contraindicated for the use of opioids.
  • Patients who are contraindicated for blood sampling.
  • Patients who are currently being maintained on methadone for pain.
  • Patients who have any planned surgery during the course of the study, with the exception of the placement of central or peripheral venous access devices.
  • Patients who have had surgery within 120 hours prior to Day 1 (day of first dose of study drug).

Other protocol-specific inclusion/exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01192295

Contacts

Contact: Deborah Steiner, MD 203-588-7413 deborah.steiner@pharma.com

Locations

United States, Arizona
Maricopa Medical Center Recruiting
Phoenix, Arizona, United States, 85008
Contact: David Rosenberg, MD
Principal Investigator: David Rosenberg, MD
United States, California
Loma Linda University Medical Center Recruiting
Loma Linda, California, United States, 92354
Contact: Peter Przekop, MD
Principal Investigator: Peter Przekop, MD
LS Packard Children's Hospital Recruiting
Palo Alto, California, United States, 94304
Contact: Elliot Krane, MD
Principal Investigator: Elliot Krane, MD
Bayview Research Group, LLC Recruiting
Paramount, California, United States, 90723
Contact: Mohammad Riaz, MD
Principal Investigator: Mohammad Riaz, MD
United States, Colorado
The Children's Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Jeffrey Galinkin, MD
Principal Investigator: Jeffrey Galinkin, MD
United States, Pennsylvania
Penn State Hershey Children's Hospital Recruiting
Hershey, Pennsylvania, United States, 17033
Contact: Andrew S. Freiberg, MD
Principal Investigator: Andrew S. Freiberg, MD
United States, Texas
Children's Medical Ctr of Dallas Recruiting
Dallas, Texas, United States, 75235
Contact: Peter Szmuk, MD
Principal Investigator: Peter Szmuk, MD
Estonia
Tallinn Children's Hospital Recruiting
Tallinn, Estonia, 13419
Contact: Kadri Saks, MD
Principal Investigator: Kadri Saks, MD
Tartu University Hospital Recruiting
Tartu, Estonia, 51014
Contact: Karin Varik, MD, Ph.D.
Principal Investigator: Karin Varik, MD, Ph.D.

Sponsors and Collaborators

Purdue Pharma LP

More Information


Additional Information:


No publications provided

Responsible Party: Purdue Pharma LP ( Medical Monitor )
ClinicalTrials.gov Identifier: NCT01192295 History of Changes
Other Study ID Numbers: OTR3001, 2010-020471-23
Study First Received: August 30, 2010
Last Updated: March 28, 2011
Health Authority: United States: Food and Drug Administration; Estonia: State Agency of Medicines


Keywords provided by Purdue Pharma LP:

Malignant pain
Nonmalignant pain
Pediatric
Opioid
Moderate to severe malignant or nonmalignant pain


Additional relevant MeSH terms:

Oxycodone
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs

Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotics


ClinicalTrials.gov processed this record on April 14, 2011

 

 

This is the recent posting of the clinical trials on children taking OxyContin --  Please note that it now indicates

This study is not yet open for participant recruitment.

Verified on June 2011 by Purdue Pharma LP

 

HomeSearchStudy TopicsGlossary



Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

This study is not yet open for participant recruitment.

Verified on June 2011 by Purdue Pharma LP

First Received on June 7, 2011. Last Updated on June 8, 2011 History of Changes

Sponsor: Purdue Pharma LP
Information provided by: Purdue Pharma LP
ClinicalTrials.gov Identifier: NCT01369615

Purpose

The purpose of this study is to characterize the long-term safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid experienced pediatric patients aged 6 to 17 years, inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy who completed the 4 -week treatment period in OTR3001.

Condition Intervention Phase
Pain
Drug: Oxycodone hydrochloride controlled-release tablets
Phase III


Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment

Masking: Open Label
Primary Purpose: Treatment

Official Title: An Open-label, Extension Study to Assess the Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children Who Completed the OTR3001 Study

Resource links provided by NLM:


Further study details as provided by Purdue Pharma LP:

Primary Outcome Measures:
  • The number of participants with adverse events as a measure of safety. [ Time Frame: Up to 6 months (during the study) and 7-10 days poststudy (safety follow-up assessment). ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 135
Study Start Date: September 2011
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Oxycodone HCl controlled-release: Experimental

Oxycodone hydrochloride (HCl) controlled-release

Intervention: Drug: Oxycodone hydrochloride controlled-release tablets
Drug: Oxycodone hydrochloride controlled-release tablets

Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.

Other Name: OxyContin


Eligibility

Ages Eligible for Study: 6 Years to 17 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria include:

  • Male and female patients aged 6 to 17 years, inclusive, who completed the 4-week study drug treatment in study OTR3001 and who, based on the investigator's judgment, will benefit from continuing treatment with oxycodone HCl CR 20 to 240 mg/day for the management of moderate to severe malignant or nonmalignant pain;
  • Patients must have tolerated the oxycodone HCl CR therapy in OTR3001 as demonstrated at the start of the study;
  • Patients must be willing and able to swallow the oxycodone HCl CR tablets whole.

Exclusion Criteria include:

  • Patients with ongoing adverse events in OTR3001 that, in the investigator's opinion, disqualify them from participation in the study;
  • Female patients who are pregnant or lactating;
  • Patients requiring opioid at doses equivalent to < 20 mg/day or > 240 mg/day oxycodone for treatment of their malignant or nonmalignant pain;
  • Patients who are allergic to oxycodone or have a history of allergies to other opioids (this criterion does not include patients who have experienced common opioid side effects [eg, nausea, constipation]);
  • Patients who are contraindicated for the use of opioids;
  • Patients who are currently being maintained on methadone for pain;
  • Patients who have an abnormality on vital signs, physical examination, or laboratory testing significant enough that the investigator deems the patient is not appropriate for the study;
  • Patients who have any planned surgery during the course of the study, with the exception of the placement of central or peripheral venous access devices;
  • Patients currently taking an investigational medication/therapy other than the study drug (oxycodone HCl CR) at the start of screening or during the study.

Other protocol specific inclusion/exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01369615

Contacts

Contact: Deborah Steiner, MD 203-588-7413 Deborah.steiner@pharma.com

Sponsors and Collaborators

Purdue Pharma LP

More Information


Additional Information:


No publications provided

Responsible Party: Medical Monitor, Purdue Pharma LP
ClinicalTrials.gov Identifier: NCT01369615 History of Changes
Other Study ID Numbers: OTR3002, 2011-002235-26
Study First Received: June 7, 2011
Last Updated: June 8, 2011
Health Authority: United States: Food and Drug Administration


Keywords provided by Purdue Pharma LP:

Malignant pain
Nonmalignant pain
Pain
Pediatric
Opioid
Moderate to severe


Additional relevant MeSH terms:

Oxycodone
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs

Pharmacologic Actions
Analgesics

Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Analgesics, Opioid


ClinicalTrials.gov processed this record on September 25, 2011

 



 

 

 




Marianne Skolek

National Activist for Victims of OxyContin

and Purdue Pharma - a criminally convicted pharmaceutical company

908-285-1232

_________________________________

Salem-News.com Reporter Marianne Skolek, is an Activist for Victims of OxyContin and Purdue Pharma throughout the United States and Canada. In July 2007, she testified against Purdue Pharma in Federal Court in Virginia at the sentencing of their three CEO's - Michael Friedman, Howard Udell and Paul Goldenheim - who pleaded guilty to charges of marketing OxyContin as less likely to be addictive or abused to physicians and patients. She also testified against Purdue Pharma at a Judiciary Hearing of the U.S. Senate in July 2007. Marianne works with government agencies and private attorneys in having a voice for her daughter Jill, who died in 2002 after being prescribed OxyContin, as well as the voice for scores of victims of OxyContin. She has been involved in her work for the past 8-1/2 years and is currently working on a book that exposes Purdue Pharma for their continued criminal marketing of OxyContin.

Marianne is a nurse having graduated in 1991 as president of her graduating class. She also has a Paralegal certification. Marianne served on a Community Service Board for the Courier News, a Gannet newspaper in NJ writing articles predominantly regarding AIDS patients and their emotional issues. She was awarded a Community Service Award in 1993 by the Hunterdon County, NJ HIV/AIDS Task Force in recognition of and appreciation for the donated time, energy and love in facilitating a Support Group for persons with HIV/AIDS.

Marianne Skolek
National Activist for Victims of OxyContin and
Purdue Pharma - a criminally convicted pharmaceutical company
Staff Writer, Salem-News.com

www.oxydeaths.com

End Israel's Unwarranted Murder of Kids




Comments Leave a comment on this story.
Name:

All comments and messages are approved by people and self promotional links or unacceptable comments are denied.



Justice September 28, 2011 8:20 am (Pacific time)

Marianne I work on the pharmaceutical industry and Pediatric studies are performed to extend patent exclusivity for 6-months. I am not saying that is right for Oxycontin, but these studies are encourage by FDA for all NDA filed. For Purdue this means extra 1.8 billion in their pocket, and assumming they spend 150 million, there is a huge gain.

[Return to Top]
©2014 Salem-News.com. All opinions expressed in this article are those of the author and do not necessarily reflect those of Salem-News.com.
comments powered by Disqus


Articles for September 26, 2011 | Articles for September 27, 2011 | Articles for September 28, 2011
Your customers are looking: Advertise on Salem-News.com!

Steele`s Karate
In Salem
Sign Up Now!

Donate to Salem-News.com and help us keep the news flowing! Thank you.

The NAACP of the Willamette Valley